A comprehensive screening procedure analyzes a biological sample, typically urine, for the presence of twelve distinct classes of illicit and prescription drugs. This type of analysis is often employed in pre-employment screenings, workplace compliance programs, and clinical settings to identify substance use. For example, such a test might detect substances like amphetamines, barbiturates, benzodiazepines, cocaine metabolites, marijuana metabolites (THC), methadone, opiates, phencyclidine (PCP), propoxyphene, tricyclic antidepressants, and synthetic opioids.
The significance of broad-spectrum drug screenings lies in their ability to provide a relatively complete overview of an individual’s recent drug use. This is beneficial in ensuring workplace safety, maintaining regulatory compliance, and assisting in medical diagnosis and treatment planning. Historically, the development of increasingly comprehensive drug tests reflects growing concerns about substance abuse and the need for accurate and reliable detection methods. The expansion from simpler assays to more encompassing panels mirrors advancements in analytical technology and the diversification of available controlled substances.
